Roche has offered to buy the 45% stake of Genentech it doesn’t already own with a $89/share, $43.7B (8.8% premium) offer.
The initial Roche/Genentech deal brokered in the 90’s has been key to Roche’s success in the last few years. Upon first blush, this deal seems a natural fit and a no-brainer for Roche but [...]
All this talk of MS in the last week has made your editor hungry for some MS info-video-graphic.
Share and Enjoy:
Recent Comments